AFQ056 + Placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Patient Diagnosed With OCD and Resistant to SSRI Treatment
Conditions
Patient Diagnosed With OCD and Resistant to SSRI Treatment, Failed SSRI Over 12 Weeks at Appropriate Doses
Trial Timeline
Nov 1, 2013 → Nov 1, 2014
NCT ID
NCT01813019About AFQ056 + Placebo
AFQ056 + Placebo is a phase 2 stage product being developed by Novartis for Patient Diagnosed With OCD and Resistant to SSRI Treatment. The current trial status is terminated. This product is registered under clinical trial identifier NCT01813019. Target conditions include Patient Diagnosed With OCD and Resistant to SSRI Treatment, Failed SSRI Over 12 Weeks at Appropriate Doses.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04771143 | Phase 1 | Withdrawn |
| NCT03242928 | Phase 2 | Completed |
| NCT02920892 | Phase 2 | Completed |
| NCT01813019 | Phase 2 | Terminated |
| NCT01491529 | Phase 2 | Completed |
| NCT01385592 | Phase 2 | Completed |
| NCT01357239 | Phase 2 | Completed |
| NCT01253629 | Phase 2 | Completed |
| NCT01019473 | Phase 2 | Terminated |
| NCT00888004 | Phase 2 | Completed |
| NCT00582673 | Phase 2 | Completed |
Competing Products
20 competing products in Patient Diagnosed With OCD and Resistant to SSRI Treatment
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| R744 + R744 | Chugai Pharmaceutical | Phase 3 | 77 |
| R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| R744 + Epoetin beta | Chugai Pharmaceutical | Phase 3 | 77 |
| R744 + R744 | Chugai Pharmaceutical | Phase 3 | 77 |
| R744 + R744 | Chugai Pharmaceutical | Phase 3 | 77 |
| R744 | Chugai Pharmaceutical | Phase 3 | 77 |
| PLX3397 + Temozolomide | Daiichi Sankyo | Phase 1/2 | 41 |
| FK949E | Astellas Pharma | Phase 1 | 33 |
| roxadustat | Astellas Pharma | Phase 3 | 77 |
| roxadustat | Astellas Pharma | Phase 3 | 77 |
| Roxadustat + Darbepoetin alfa | Astellas Pharma | Phase 3 | 77 |
| ASP8825 | Astellas Pharma | Phase 1 | 33 |
| ASP015K | Astellas Pharma | Phase 1 | 33 |
| ASP7991 | Astellas Pharma | Phase 1 | 33 |
| Roxadustat + Epoetin Alfa | Astellas Pharma | Phase 3 | 77 |
| ATG-F | Astellas Pharma | Approved | 85 |
| Celecoxib | Astellas Pharma | Pre-clinical | 23 |
| roxadustat + Darbepoetin alfa | Astellas Pharma | Phase 3 | 77 |
| roxadustat | Astellas Pharma | Phase 3 | 77 |
| FK949E | Astellas Pharma | Phase 1 | 33 |